Pfizer, Inc. (PFE) Stock Guide
Updated: December 02, 2021
Bull case
Revenue growth higher than the industry and sector averages
Company’s profitability is improving
Forward dividend yield higher than the industry and sector averages
Forward PEG ratio low relative to industry peers
Buy analyst rating
Bear case
Stock price high relative to the 52-week range
Forward P/S ratio high relative to industry peers
Average analyst stock price below current stock price
High short interest

Before we start: if you're looking for PFE stock price, you can quickly find it out by visiting Finny and typing "PFE quote". If you're looking for a quick scoop on PFE stock (chart, price target, market cap, news and buy or sell analysis), go to Finny and look for "PFE". You'll get all this info in one place. Or you can just type "PFE news" to get the latest stock news.

Looking to buy or sell Pfizer, Inc. (PFE)? Interested in getting the full scoop on PFE, including earnings and dividends, stock forecast, buy or sell analysis and key stats? If so, you came to the right place.

In this PFE stock guide, we'll address key questions about PFE, above and beyond what you can find on Yahoo Finance, Zacks, MarketWatch or Morningstar.

Here is what you'll be able to find in this guide:

Earnings and Dividends: earnings, earnings date, dividend rate and dividend yield;
Analyst Predictions: stock forecast and analyst ratings;
Analysis: Finny Score and buy or sell analysis;
Key Stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio, industry, sector, and number of employees.

And here is the list of questions we'll answer:
1. What are PFE earnings?
2. When is PFE earnings date?
3. What is PFE dividend?
4. What is PFE dividend yield?
5. What is PFE stock forecast (i.e., prediction)?
6. PFE buy or sell? What is PFE Finny Score?
7. What are the reasons to buy PFE? Why should I buy PFE stock?
8. What are the reasons to sell PFE? Why should I sell PFE stock?
9. What are PFE key stats: revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

So let's start. Scroll down to the question that interests you the most.

Earnings and Dividends

1. What are PFE earnings?

PFE trailing 12-month earnings per share (EPS) is $1.97.

2. When is PFE earnings date?

PFE earnings date is January 31, 2022.

3. What is PFE dividend?

PFE forward dividend is $1.56.

4. What is PFE dividend yield?

PFE forward dividend yield is 3.98%.

Analyst Predictions

5. What is PFE stock forecast (i.e., prediction)?

Based on PFE analyst price targets, PFE stock forecast is $49.60 (for a year from now). That means the average analyst price target for PFE stock is $49.60. The prediction is based on 23 analyst estimates.

The low price target for PFE is $42.00, while the high price target is $61.00.

PFE analyst rating is Buy.

Analysis

6. PFE buy or sell? What is PFE Finny Score?

Our quantitative analysis shows 5 reasons to buy and 4 reasons to sell PFE, resulting in Finny Score of 56.

7. What are the reasons to buy PFE? Why should I buy PFE stock?

Here are the reasons to buy PFE stock:

  • Pfizer's pipeline productivity is improving with several successful recent launches. In particular, Xeljanz is a potential game-changer in rheumatoid arthritis. In addition, Ibrance should develop into a major blockbuster in breast cancer.
  • The stock supports a dividend yield of over 3% and we expect the dividend payout ratio will remain largely stable over next several years.
  • While Pfizer decided against breaking up the company into an innovative core and an established drug group, the increased visibility of the segments and the option to revisit the decision creates potential value.
  • Pfizer’s October 2009 acquisition of Wyeth helped the company become more diversified with a stronger presence in emerging markets. The company also enhanced its pipeline and created a lower and more flexible cost base. Wyeth’s large biologics platform, strong presence in vaccines, and significant consumer products businesses has been beneficial for Pfizer.
  • In addition to acquisitions, Pfizer is looking to drive growth through licensing deals and collaborative agreements. Pfizer has a deal with Merck for Steglatro/ertugliflozin which was approved in the United States in December 2017 for treatment of type II diabetes as a monotherapy and also in two fixed-dose combinations with metformin and with Januvia/sitagliptin. Steglatro/ertugliflozin is under review in the EU.
  • Pfizer has committed more resources toward the development of treatments in the fields of oncology, metabolic disease and cardiovascular risks, rare diseases, immunology, inflammation and vaccines as well as immuno-oncology. Most of these are areas in which the company believes it can take leading positions. The company has also stopped funding treatments for high risk/low productivity therapeutic areas like neuroscience, allergy, respiratory diseases, urology, internal medicine and tissue repair.
  • With several of its products either facing or slated to face generic competition, Pfizer is looking toward cost- cutting initiatives to drive bottom-line growth. Pfizer has been undertaking massive restructuring and cost-cutting over the past several years. Management is also looking to focus its efforts on areas that may offer the most potential like oncology and geographic regions like Asia.
  • Pfizer is also looking to reward shareholders through share buybacks and dividends. The company returned about $13.1 billion to shareholders in the form of dividends and share buybacks in 2015, $12.3 billion in 2016, and 12.7 billion in 2017. In 2018, the company expects to buy back shares worth $5 billion.
  • PFE quarterly revenue growth was 44.60%, higher than the industry and sector average revenue growth (5.24% and 5.21%, respectively). See PFE revenue growth chart.
  • PFE profitability is improving. The YoY profit margin change was 26.89 percentage points. See PFE profitability chart.
  • PFE forward dividend yield is 3.98%, higher than the industry (0.63%) and sector (0.12%) forward dividend yields. See PFE forward dividend chart.
  • PFE PEG ratio (P/E adjusted for growth) is 0.92, which is low compared to its industry peers’ PEG ratios. See PFE PEG chart.
  • PFE average analyst rating is Buy. See PFE analyst rating chart.

8. What are the reasons to sell PFE? Why should I sell PFE stock?

Let's look at the reasons to sell PFE stock (i.e., the bear case):

  • Pfizer's aggressive cost-cutting in research and development could hurt the long-term prospects of the firm as less capital is available to develop the company's next generation of drugs.
  • Although the company is through the worst of its patent cliff, Pfizer still faces major patent losses with Viagra in 2017 and Lyrica in 2019.
  • Several of Pfizer's late-stage pipeline drugs are entering crowded markets that may limit market share gains due to the lost first mover advantage.
  • Pfizer's top-line will continue to be impacted by the loss of patent exclusivity on products like Celebrex, Lipitor, Norvasc, Protonix, Camptosar, Pristiq and Zoloft. These products are all facing declining sales due to generic competition.
  • Although Pfizer is among the major players in immunotherapy, there are several other companies, big as well as small, looking to develop and bring immunotherapy treatments to market. Though Pfizer’s growing immuno-oncology portfolio holds great potential, many of these assets are a few years away from commercialization. Rising competition in the immuno-oncology market is a significant concern.
  • While Pfizer invests a significant amount of dollars in its pipeline, we believe that new product launches may not be sufficient to make up for the loss of revenues that will take place in the next few years. Additionally, we are disappointed with some high profile pipeline failures in the CNS category including insomnia drug Indiplon and antipsychotic asenapine. Pfizer’s CNS franchise has been significantly impacted by the loss of exclusivity on Zoloft and the failure of these two candidates.
  • PFE stock price ($54.54) is close to the 52-week high ($54.68). Perhaps now is a good time to sell? See PFE price chart.
  • PFE Price/Sales ratio is 6.20, which is high compared to its industry peers’ P/S ratios. See PFE forward Price/Sales ratio chart.
  • PFE average analyst price target ($49.60) is below its current price ($54.54). See PFE price target chart.
  • PFE short interest (days to cover the shorts) ratio is 2.62. The stock garners more short interest than the average industry, sector or S&P 500 stock. See PFE short interest ratio chart.

Key Stats

9. What are PFE key stats : revenue, market cap, revenue growth, profit margin, P/E ratio, P/B ratio industry, sector, and number of employees?

Let's look at the key statistics for PFE:

Price $53.56
Industry Drug Manufacturers - Major
Sector Healthcare
Average Price Target / Upside $49.60 / -7.39%
Average Analyst Rating Buy
Number of Employees 92,400
Forward Dividend Yield 3.98%
Market Cap $287.78B
Forward P/E Ratio 14.86
Price/Book Ratio 6.20
Revenue (TTM) $46.41B
YoY Quarterly Revenue Growth 44.60%
Profit Margin 24.00%

If you liked this analysis, check out Stock Guides for other stocks.